Tenax Therapeutics, Inc. · NASDAQ:TENX

Tenax Therapeutics — Oxygen Biotherapeutics — Shareholder Meeting (August 2012)

8 slides from Tenax Therapeutics's shareholder meeting presentation, Aug 31, 2012

  1. Slide 1: Annual Meeting of Stockholders

    Annual Meeting of Stockholders Friday, August 31, 2012 Raleigh, NC

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This Presentation contains forward looking statements which reflect the Company’s plans, goals and expectations as of this date. All statements other than statements of historical facts which address the Company’s expectations on such matters as sources of capital, the Company’s pla

  3. Slide 3: Addressing the Clinical Hold

    Addressing the Clinical Hold FDA has two major concerns: thrombocytopenia and immunocompetence  OBI has planned preclinical program to address all concerns.  Effects of platelet transfusion in treating thrombocytopenia in ICH rat model  Platelet distribution in non-human primates with acute syste

  4. Slide 4: DoD-funded Preclinical Studies–Goal to Lift FDA Hold

    DoD-funded Preclinical Studies–Goal to Lift FDA Hold  Bioanalytical Method Development:  GLP-validated bioanalytical method for detection of FtBu in rat whole blood was completed in June 2012. Method used to analyze rat PK study samples.  Qualified bioanalytical method for detection of FtBu in mo

  5. Slide 5: DoD-funded Preclinical Studies–Goal to Lift FDA Hold: In Vitro Platelet Function

    DoD-funded Preclinical Studies–Goal to Lift FDA Hold  In Vitro Platelet Function using Blood from Normal Healthy Volunteers (NHV) and TBI patients:  NHV protocol completed Jan. 2012; IRB approval Feb. 2012; FDA approval received April 2012. Protocols contain 5 in vitro platelet function assays. 

  6. Slide 6: DoD-funded Preclinical Studies–Goal to Lift FDA Hold

    DoD-funded Preclinical Studies–Goal to Lift FDA Hold  Platelet Biodistribution Study in Baboon model of Acute Systemic Inflammation:  Baboon study to be conducted at SNPRC/THSI. Site visit completed.  Model development protocol undergoing IACUC review. ACURO review planned for Sept. 2012. Determi

  7. Slide 7: Army Funded Research Program

    Army Funded Research Program June 30, 2011 June 30, 2012 July 2013 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Bioanalytical Assay Development/Validation *PK Studies in Rat and Mouse *Immunocompetence Studies in Mice *Platelet Distribution Study in Baboons *Platelet Transfusion Study in Rat *In Vitro Platelet Function

  8. Slide 8: Thank you.

    , Oxygen Biotherapeutics’ Thank you.

Oxygen Biotherapeutics — Shareholder Meeting (August 2012) on 6ix